Navigation Links
New Clinical Data Shows Significant Improvement in the Appearance of Fat Using SlimLipo(TM) Laser

SlimLipo laser-assisted liposuction offers patients better results and quicker recovery as compared to traditional liposuction and other liposuction systems currently on the market; Now available in powerful 40 watt model

BURLINGTON, Mass., May 21 /PRNewswire-FirstCall/ -- Palomar Medical Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, announced today the success of a clinical study showing the benefits of the SlimLipo body sculpting laser for laser-assisted lipolysis. Cleared by the Federal Drug Administration (FDA) in April of 2008, the SlimLipo laser is now available with 40 watts of power for faster, more effective treatments.

SlimLipo is equipped with the dual laser wavelengths of 924 nm and 975 nm for preferential absorption by fat and dermal tissue, respectively, resulting in efficient fat 'melting' with less contour deformities and faster patient recovery, as seen by a recent study published in US Dermatology, by Dr. Robert Weiss, Director of the Maryland Laser, Skin, and Vein Institute. Dr. Weiss' study found that all of the subjects agreed that the SlimLipo treatment significantly improved the appearance of fat.

"This study proved what I'd been experiencing in my own practice; patients are extremely satisfied with the results, not to mention the improvement in recovery time," said Dr. Weiss. "The study found a decrease in bruising, tenderness and swelling -- all the patients returned to work the next day," he continued.

SlimLipo allows physicians to remove excess fat and tighten the skin through laser-assisted lipolysis in one step. In fact, the study by Dr. Weiss found that patients felt a difference in the smoothness (83 percent) and tightness of their skin (67 percent) right after the SlimLipo treatment, with 100 percent of patients seeing an improvement in skin's smoothness and tightness in three months after the laser treatment.

Brooke Seckel MD, plastic surgeon at Boston Plastic Surgery Associates, Concord MA, agreed, "SlimLipo is a tremendous advancement in liposuction. The most important benefit for me is the absence of contour deformities; the skin remains smooth with no ripples or dents even in very thin patients. Couple that with the added benefit of skin tightening and SlimLipo has certainly transformed my practice."

SlimLipo requires far less physical strain for physicians than traditional liposuction. In addition, the interchangeable treatment tip design gives physicians more control, facilitating treatment of hard-to-reach areas such as the neck or pectorals.

"There is an emerging demand for this kind of treatment option among consumers -- people want stellar results, but do not want to have to take time out of their lives to achieve those results," noted Richard Bankowski, Field Clinical Director for Palomar. "SlimLipo is the best fat reduction method on the market because its technology effectively 'melts' fat for easy aspiration, even in challenging areas of the body, and helps tighten skin."

Marketing Push

Palomar will be rolling out a multi-faceted consumer-facing marketing initiative in the coming months that brands the SlimLipo procedure as LifeSculpt. The campaign will emphasize the superior results offered by the LifeSculpt procedure and will highlight how the treatment can fit into even the most active of lifestyles. In addition, a robust consumer-facing Web site, which will include "before" and "after" photos, and find-a-physician functionality, will launch at the end of May.

About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has granted The Procter & Gamble Company a non-exclusive License Agreement to certain patents, technology and FDA documents related to the home-use, light-based hair removal field for women. In addition, Palomar has an exclusive development and license agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.

For more information on Palomar and its products, visit Palomar's website at To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations section of the website.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current expectations, plans, intentions, beliefs or predictions. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, including patent infringement lawsuits, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2008 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE Palomar Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... of the leading plastic surgery practices in Florida, is proud to announce that ... for surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon ...
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three ... learned from three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint ...
(Date:11/30/2015)... ... , ... Sikka Software announced today that they are showcasing the Sikka Software ... complex business decisions by providing the tools and information they need to grow their ... procedures customized by zip code. , The Sikka Software Ecosystem includes over 32 ...
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational ... it is so important to this key industry segment, Regis Technologies has decided to ... on December 4th at 11am EST. , Federal law does not allow new drugs ...
(Date:11/30/2015)... EMIGSVILLE, PA (PRWEB) , ... November 30, 2015 ... ... (CCMS) software provider, has verified that their Vasont Universal Integrator (VUI) extension unites ... handle creating, editing, and managing content as a continuous process with the latest ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)...  Hanger, Inc. (NYSE: HGR ) (the "Company") ... of its previously announced consent solicitation (as amended and ... principal amount 7⅛% Senior Notes due 2018 (the "Notes") ... payable pursuant to the Consent Solicitation, (ii) the proposed ... expiration date of the Consent Solicitation.    ...
(Date:11/30/2015)... 2015  Novartis will demonstrate the strength of its ... American Society of Hematology (ASH) Annual Meeting. Presentations will ... as supportive care, including key findings in rare and ... The ASH Annual Meeting will be held December 5-8 ... Novartis Oncology . "We will be presenting encouraging overall ...
(Date:11/30/2015)... , Nov. 30, 2015   VolitionRx Limited (NYSE ... diagnostic tests for a broad range of cancer types and ... LD Micro Conference, which will be held December 1 - 3 ... from VolitionRx will be David Kratochvil , Chief Financial ... of Investor Relations. ® blood-based tests for ...
Breaking Medicine Technology: